Arbutus receives FDA Fast Track designation for imdusiran in chronic hepatitis B

Arbutus Biopharma Corp

FDA granted Fast Track designation for imdusiran, an investigational therapy for chronic hepatitis B.
Imdusiran has achieved functional cure in 10 chronic HBV patients in clinical trials to date.
Fast Track may enable Accelerated Approval, Priority Review, or Rolling Review of a BLA or NDA.
CEO Lindsay Androski said designation validates imdusiran as an important drug candidate.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.